Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
19 April 2021Website:
http://www.ginkgobioworks.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 68 min agoDividend
Analysts recommendations
Institutional Ownership
DNA Latest News
Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63 in the latest trading session, marking a -1.55% move from the prior day.
Dublin, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The "DNA & RNA Banking Services Market Size, Share and Trends Analysis Report by Service, Specimen (Blood, Buccal Swabs & Hair Follicles, Others), Application, End-use 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global DNA & RNA banking services market size is expected to reach USD 10.92 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030.
Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers
STONY BROOK, NY / ACCESSWIRE / October 15, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA"), a leader in PCR-based DNA technologies, today announced that Dr. James A. Hayward, president and chief executive officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to 24 classes from Freddie Mac Structured Agency Credit Risk (STACR®) REMIC 2024-DNA3 Notes, Freddie Mac STACR REMIC Trust 2024-DNA3 (STACR 2024-DNA3), a credit risk sharing transaction with a total note offering of $642,500,000. STACR 2024-DNA3 features loans with loan-to-value (LTV) ratios greater than 60%, but less than or equal to 80%. The Offered Notes represent obligations of the STACR 2024-DNA3 Trust in a credit-linked note stru.
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.70, moving -0.77% from the previous trading session.
PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercialize set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolation of cell-free DNA // Cell-free DNA in urine can provide important information to data not found in blood samples
OAKLAND, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA):
BOSTON , Sept. 18, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, proudly announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient.
The biotech rolled out two new healthtech innovations. One is a large language model (LLM) developed with its partner Alphabet.
What type of business is Ginkgo Bioworks Holdings?
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
What sector is Ginkgo Bioworks Holdings in?
Ginkgo Bioworks Holdings is in the Healthcare sector
What industry is Ginkgo Bioworks Holdings in?
Ginkgo Bioworks Holdings is in the Biotechnology industry
What country is Ginkgo Bioworks Holdings from?
Ginkgo Bioworks Holdings is headquartered in United States
When did Ginkgo Bioworks Holdings go public?
Ginkgo Bioworks Holdings initial public offering (IPO) was on 19 April 2021
What is Ginkgo Bioworks Holdings website?
https://www.ginkgobioworks.com
Is Ginkgo Bioworks Holdings in the S&P 500?
No, Ginkgo Bioworks Holdings is not included in the S&P 500 index
Is Ginkgo Bioworks Holdings in the NASDAQ 100?
No, Ginkgo Bioworks Holdings is not included in the NASDAQ 100 index
Is Ginkgo Bioworks Holdings in the Dow Jones?
No, Ginkgo Bioworks Holdings is not included in the Dow Jones index
When was Ginkgo Bioworks Holdings the previous earnings report?
No data
When does Ginkgo Bioworks Holdings earnings report?
The next expected earnings date for Ginkgo Bioworks Holdings is 08 November 2024